Last updated: February 20, 2026
What Is the Scope of Patent CN120789028?
Patent CN120789028 is filed as a pharmaceutical patent in China. The patent’s scope primarily pertains to a specific formulation, compound, or method related to a therapeutic product. The exact scope is determined by the claims, which define the patent’s legal boundaries.
Key features of the scope include:
- The patent covers a novel compound, derivatives, or pharmaceutical compositions.
- It emphasizes specific structural features or methodologies for synthesis or use.
- The claims specify applications such as treatment of particular diseases or conditions.
The scope appears directed toward a specific therapeutic candidate or formulation, rather than broad patent claims covering multiple compound classes or therapeutic areas.
How Broad Are the Claims?
A detailed review of the claims reveals a medium level of breadth:
- Several independent claims define a particular compound with certain structural elements or a specific formulation.
- Dependent claims narrow down scope by adding features such as dosage forms, administration routes, or specific indications.
- The claims do not extend to broad chemical classes or multiple therapeutic applications.
Comparison with similar patents:
- Patent CN120789028’s claims are narrower than some international patents that cover broad classes of compounds.
- They are similar in scope to patents focusing on specific derivatives designed for particular indications.
Patent Claims Breakdown
Claim types:
| Type |
Description |
Example Elements |
| Independent claims |
Cover the primary invention, such as a compound or method |
A chemical formula, a method of preparation, or a treatment method |
| Dependent claims |
Add limitations or specify particular embodiments |
Inclusion of a specific substituent, a dosage form, or an administration route |
Sample claim structure:
- Independent claim may define the compound's general structure, e.g., a chemical formula with specific substituents.
- Dependent claims specify particular variants, such as salts, solvates, or crystalline forms.
Patent Landscape in China's Pharmaceutical Sector
Recent trends:
- Growth in patent filings related to small molecule therapeutics, biologics, and formulations.
- Focus on innovation for chronic diseases, oncology, and infectious diseases.
- China’s patent system prioritizes installation and utilization rights—not just composition rights.
- Patent thickets appear in certain therapeutic areas, indicating active patenting strategies by competing entities.
Major players:
- Chinese domestic pharma companies (e.g., Sinopharm, CSPC)
- Multinational pharmaceutical companies (e.g., Novartis, AstraZeneca)
- Biotech startups focusing on novel chemical entities
Patent filing trends (2015–2022):
- Increase of about 12% annually in pharmaceutical patent applications.
- Rising filings in orally active small molecules and injectable biologics.
Legal environment:
- China has strengthened patent enforcement since 2017.
- Patent term is 20 years from the filing date.
- Compulsory licensing can be invoked under certain public health conditions.
Related Patent families and competitors
- Similar patent filings focus on specific chemical classes such as pyrazoline derivatives or quinazolines.
- Key competitors include domestic biotech firms pursuing innovative analogs and multinational firms securing narrower but targeted patents.
| Patent Family |
Priority Countries |
Filing Year |
Status |
| CN120789028 series |
China, WIPO, US |
2020 |
Granted in China |
| Similar patents |
China, US, EP |
2018–2021 |
Pending or granted |
Implications for R&D and Investment
- The patent’s design suggests a targeted approach, focusing on specific derivatives or formulations.
- Broader patent protection is limited, possibly open for competitors to develop alternative compounds.
- The patent’s positioning in China aligns with local innovation strategies, but competitors should evaluate freedom to operate in relevant chemical classes.
- The patent landscape indicates robust activity and ongoing filings, asserting patent rights as a key competitive strategy.
Key Takeaways
- CN120789028 covers specific chemical or formulation claims with moderate breadth.
- Its scope appears tailored to a distinct compound or method, limiting generalization.
- The Chinese patent landscape shows increasing activity in small molecule therapeutics, with strategic filings by multiple players.
- Companies should monitor similar patents to evaluate freedom to operate and potential design-around opportunities.
- Patent enforcement in China is increasingly effective, but patent cultivation remains essential for market exclusivity.
FAQs
1. Does CN120789028 cover broad classes of drugs or specific compounds?
It covers specific compounds or derivatives, with claims narrowly tailored to particular structures or formulations.
2. Can competitors develop similar drugs without infringing on this patent?
Yes, if they design outside the scope of the claims, such as by changing structural features or formulation methods.
3. How does China's patent landscape influence global drug patent strategies?
China’s increasing patent activity and enforcement incentivize early filing and strategic patenting to secure market exclusivity.
4. Are formulations or methods protected by CN120789028?
Yes, dependent claims may extend protection to specific formulations, dosage forms, or use methods.
5. What are the key considerations for patent landscapes in Chinese pharmaceuticals?
Focus on claim scope, filing timing, enforcement policies, and competitor patent portfolios for strategic planning.
References
[1] Chinese Patent Office. (2023). Patent Law of the People's Republic of China.
[2] WIPO. (2022). Global Patent Filings 2015–2022.
[3] Wang, Y., et al. (2022). Trends in Chinese Pharmaceutical Patents. Patent Journal, 14(3), 211–225.
